Help Finding Clinical Trials
Having applied for a couple of trials and searching for new ones, I now realize I need help navigating these clinical trial options and doing this takes a great amount of time and expertise. I am doing as much as I can on my end, but it is overwhelming and I need more help. I am now having a recurrence and am considered Stage 4 so I am keenly aware that time is of the essence and the windows of opportunity for me to get into any trials are closing rapidly.
I think what I really need is to personally hire a part-time or full-time person to navigate through clinical trials. Do you know someone or have any recommendations on how to find someone (located anywhere), who has the expertise and can take the lead in determining appropriate trials and making direct contact with study coordinators and principal investigators to expedite the determination of my eligibility, the availability of slots, and guide through the process? Would this role be called "clinical coordinator" or something else?
If you have any suggestions about how to find someone I can personally hire to help me, I would be most grateful. StageIVSurvivor, perhaps you know someone or how to find someone?
Beth
Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.
A clinical trial is to compare a new treatment or drug to an existing one if one currently exists. Or the trial can be a new class of drug for which no prior treatment exists. A trial is conducted in three phases with phase III more closely resembling real-world conditions. Conducting trials are costly and time consuming to collect the required amount of data for biostatistical analysis to determine if the new drug offers significant improvement and is as safe or safer.
There may be other companies testing a biosimilar compound. A case in point is the drug Olaparib (Lynparza) made by Astra Zeneca and the biosimilar compound Rucaparib (Rubraca) by Clovis Oncology. Astra Zeneca had a significant head start and is a much larger, cash-rich Pharma company. Their head start led to generating the required data and submitting it to the FDA which led to approved use for a number of cancers including pancreatic.
Clovis was a new entry and a small bio pharmaceutical company. They were testing their compound on Ovarian and breast cancers when it was learned there was potential for treating pancreatic cancer in what is a very small cohort.
With a well established Pharma company already having 100% of the available cohort to sell their Rx drug, a smaller company with the same drug is faced with trying to use critical funds to get approval for ovarian and breast which is a larger cohort for fighting to gain market share.
Now imagine if you are the head of a small bio Pharma with limited funding. Do you dilute critical resources and try to go after a tiny population of pancreatic cancer patients with mutations that may respond to a PARP inhibitor and jeopardize getting the drug through the breast cancer trials so application can be made to the FDA where approval could mean gaining a market share of a bigger patient cohort? It sometimes comes down to a make or break decision and whether a company survives. Bottom line-there is an FDAapproved PARP inhibitor available and helping pancreatic cancer patients with targetable mutations now. Another fact is it takes about 13 years from the discovery of a bio active compound to receive FDA approval.
To get a drug through FDA approval is also very expensive. Every time filings of documents are made to the FDA, it is not a one-time fee that covers the submission. It costs millions of dollars to cover those filings.
Yes my husband has stage 4 pancreatic cancer, he is a fighter and we are looking. We are located in WA state. We are willing to travel.
I have been trying to get into a new trial for xtx301 IL-12.Haven't gotten any answer to emails.
which trial did you do?
Is this the trial?
- Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer https://clinicaltrials.gov/ct2/show/NCT03281382
It looks like recruitment is completed for this trial. Or is their another trial, @pendesk8?
The trial was RucaPANC for maintenance monotherapy and targeted BRCA1, BRCA2, PALB2 mutations using the PARP-1 inhibitor Rucaparib (Rubraca).
More details on the trial-
PARP STUDY AT PennMedicine
https://ascopubs.org/doi/10.1200/PO.17.00316
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057747/
This is a YouTube video of my case by pancreatic cancer oncologist Dr. Kim Reiss-Binder at PennMedicine. It starts at time stamp 1:00 and the conclusion is at the end of the presentation.
Hope this is on a fast track to get approval.
thats the wrong one.This is a brand new trial starting in January 2023.from xilio.
thank you .
Outstanding!!!!!! I will send to family members with BRCA1.